Asia-Pacific: Antisera Market 2024

Antisera Market Size in Asia-Pacific

The Asia-Pacific antisera market totaled $X in 2022, with an increase of X% against the previous year. Overall, consumption continues to indicate a resilient increase. Over the period under review, the market hit record highs in 2022 and is likely to see steady growth in the immediate term.

Antisera Production in Asia-Pacific

In value terms, antisera production totaled $X in 2022 estimated in export price. In general, production, however, continues to indicate a prominent increase. The most prominent rate of growth was recorded in 2020 when the production volume increased by X% against the previous year. As a result, production reached the peak level of $X. From 2021 to 2022, production growth failed to regain momentum.

Antisera Exports

Exports in Asia-Pacific

In 2022, overseas shipments of antisera and other blood fractions decreased by X% to X tons for the first time since 2018, thus ending a three-year rising trend. Overall, exports, however, posted a significant increase. The most prominent rate of growth was recorded in 2021 with an increase of X%. As a result, the exports reached the peak of X tons, and then shrank markedly in the following year.

In value terms, antisera exports plummeted to $X in 2022. Over the period under review, exports, however, showed significant growth. The most prominent rate of growth was recorded in 2020 with an increase of X% against the previous year. The level of export peaked at $X in 2021, and then dropped sharply in the following year.

Exports by Country

China was the main exporting country with an export of around X tons, which resulted at X% of total exports. Singapore (X tons) held the second position in the ranking, followed by South Korea (X tons). All these countries together held approx. X% share of total exports. New Zealand (X tons) and India (X tons) followed a long way behind the leaders.

Exports from China increased at an average annual rate of X% from 2012 to 2022. At the same time, South Korea (X%), Singapore (X%), India (X%) and New Zealand (X%) displayed positive paces of growth. Moreover, South Korea emerged as the fastest-growing exporter exported in Asia-Pacific, with a CAGR of X% from 2012-2022. South Korea (X p.p.), China (X p.p.) and Singapore (X p.p.) significantly strengthened its position in terms of the total exports, while India and New Zealand saw its share reduced by X% and X% from 2012 to 2022, respectively.

In value terms, the largest antisera supplying countries in Asia-Pacific were South Korea ($X), Singapore ($X) and China ($X), with a combined X% share of total exports.

Among the main exporting countries, South Korea, with a CAGR of X%, saw the highest rates of growth with regard to the value of exports, over the period under review, while shipments for the other leaders experienced more modest paces of growth.

Export Prices by Country

The export price in Asia-Pacific stood at $X per ton in 2022, increasing by X% against the previous year. In general, the export price posted tangible growth. The level of export peaked at $X per ton in 2019; however, from 2020 to 2022, the export prices stood at a somewhat lower figure.

Prices varied noticeably by country of origin: amid the top suppliers, the country with the highest price was South Korea ($X per ton), while China ($X per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was attained by India (X%), while the other leaders experienced more modest paces of growth.

Antisera Imports

Imports in Asia-Pacific

After ten years of growth, purchases abroad of antisera and other blood fractions decreased by X% to X tons in 2022. Overall, imports, however, posted a buoyant expansion. The most prominent rate of growth was recorded in 2021 with an increase of X%. As a result, imports attained the peak of X tons, and then reduced in the following year.

In value terms, antisera imports rose slightly to $X in 2022. Over the period under review, imports, however, showed resilient growth. The most prominent rate of growth was recorded in 2019 when imports increased by X%. Over the period under review, imports attained the peak figure in 2022 and are expected to retain growth in the immediate term.

Imports by Country

In 2022, China (X tons), distantly followed by Australia (X tons), Taiwan (Chinese) (X tons), Singapore (X tons), Japan (X tons), the Philippines (X tons) and South Korea (X tons) were the main importers of antisera and other blood fractions, together comprising X% of total imports. Malaysia (X tons) followed a long way behind the leaders.

From 2012 to 2022, the most notable rate of growth in terms of purchases, amongst the main importing countries, was attained by the Philippines (with a CAGR of X%), while imports for the other leaders experienced more modest paces of growth.

In value terms, Japan ($X), China ($X) and Australia ($X) were the countries with the highest levels of imports in 2022, together accounting for X% of total imports. South Korea, Taiwan (Chinese), Singapore, the Philippines and Malaysia lagged somewhat behind, together comprising a further X%.

The Philippines, with a CAGR of X%, recorded the highest growth rate of the value of imports, in terms of the main importing countries over the period under review, while purchases for the other leaders experienced more modest paces of growth.

Import Prices by Country

The import price in Asia-Pacific stood at $X per ton in 2022, growing by X% against the previous year. Over the last decade, it increased at an average annual rate of X%. The pace of growth was the most pronounced in 2019 when the import price increased by X%. As a result, import price reached the peak level of $X per ton. From 2020 to 2022, the import prices remained at a lower figure.

Prices varied noticeably by country of destination: amid the top importers, the country with the highest price was Japan ($X,598 per ton), while the Philippines ($X per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was attained by South Korea (X%), while the other leaders experienced more modest paces of growth.

Source: IndexBox Platform

Frequently Asked Questions (FAQ) :